The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Table 5

Budget impact in thousands € with denosumab.

	2010	2011	2012	2013
Medications	—	−3,766	−5,854	−9,385
Inpatient care	—	−1,174	−2,025	−3,383
Outpatient care	—	−250	−420	−689
Community care	—	—	−624	−1,447
Total	—	−5,190	−8,923	−14,904